Perceptive Advisors Boosted Puma Biotechnology (PBYI) Position By $22.67 Million; Geron (GERN) Sentiment Is 0.97

February 21, 2018 - By Vivian Park

Geron Corporation operates as a biopharmaceutical company. The company has market cap of $358.27 million. The firm supports the clinical stage development of a telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It currently has negative earnings. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses.

Perceptive Advisors Llc increased Puma Biotechnology Inc (PBYI) stake by 25.98% reported in 2017Q3 SEC filing. Perceptive Advisors Llc acquired 190,500 shares as Puma Biotechnology Inc (PBYI)’s stock declined 6.09%. The Perceptive Advisors Llc holds 923,820 shares with $110.63M value, up from 733,320 last quarter. Puma Biotechnology Inc now has $2.52B valuation. The stock increased 0.07% or $0.05 during the last trading session, reaching $67.1. About 400,059 shares traded. Puma Biotechnology, Inc. (NYSE:PBYI) has risen 23.65% since February 21, 2017 and is uptrending. It has outperformed by 6.95% the S&P500.

Analysts await Geron Corporation (NASDAQ:GERN) to report earnings on March, 7. They expect $-0.04 EPS, up 20.00% or $0.01 from last year’s $-0.05 per share. After $-0.04 actual EPS reported by Geron Corporation for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Carl Domino Inc holds 0.11% of its portfolio in Geron Corporation for 41,000 shares. Nj State Employees Deferred Compensation Plan owns 280,000 shares or 0.11% of their US portfolio. Moreover, Family Management Corp has 0.04% invested in the company for 25,200 shares. The Massachusetts-based Fernwood Investment Management Llc has invested 0.02% in the stock. Brave Asset Management Inc, a New Jersey-based fund reported 12,900 shares.

The stock increased 0.45% or $0.01 during the last trading session, reaching $2.25. About 1.04M shares traded. Geron Corporation (GERN) has risen 13.81% since February 21, 2017 and is uptrending. It has underperformed by 2.89% the S&P500.

Among 11 analysts covering Puma Biotechnology Inc (NYSE:PBYI), 9 have Buy rating, 0 Sell and 2 Hold. Therefore 82% are positive. Puma Biotechnology Inc had 57 analyst reports since August 27, 2015 according to SRatingsIntel. On Wednesday, April 19 the stock rating was maintained by Credit Suisse with “Outperform”. RBC Capital Markets maintained it with “Hold” rating and $9200 target in Wednesday, August 9 report. The firm has “Buy” rating given on Sunday, September 10 by Stifel Nicolaus. Cowen & Co upgraded the shares of PBYI in report on Thursday, May 25 to “Outperform” rating. The rating was downgraded by RBC Capital Markets on Tuesday, March 29 to “Sector Perform”. J.P. Morgan maintained it with “Buy” rating and $131.0 target in Wednesday, October 4 report. Stifel Nicolaus upgraded Puma Biotechnology, Inc. (NASDAQ:PBYI) on Wednesday, September 21 to “Buy” rating. The stock of Puma Biotechnology, Inc. (NASDAQ:PBYI) has “Overweight” rating given on Thursday, August 27 by JP Morgan. Cowen & Co maintained it with “Buy” rating and $123.0 target in Thursday, November 9 report. RBC Capital Markets maintained the stock with “Hold” rating in Monday, June 5 report.

Since September 6, 2017, it had 0 insider buys, and 6 sales for $4.70 million activity. 15,000 shares were sold by BRYCE RICHARD PAUL, worth $1.50M on Wednesday, September 6. 10,692 shares were sold by AUERBACH ALAN H, worth $991,683. 1,858 Puma Biotechnology, Inc. (NASDAQ:PBYI) shares with value of $172,515 were sold by Lo Steven. EYLER CHARLES R had sold 669 shares worth $62,117 on Monday, January 22.

Investors sentiment increased to 1.55 in Q3 2017. Its up 0.34, from 1.21 in 2017Q2. It improved, as 19 investors sold PBYI shares while 41 reduced holdings. 41 funds opened positions while 52 raised stakes. 35.70 million shares or 3.15% more from 34.61 million shares in 2017Q2 were reported. Perceptive Advisors Ltd invested in 4.22% or 923,820 shares. Redmile Grp Incorporated Ltd Llc holds 5.36% or 906,642 shares in its portfolio. Stifel accumulated 0% or 1,744 shares. Rock Springs Cap Mngmt Limited Partnership has 330,000 shares. Oppenheimer Asset Mgmt invested in 241 shares or 0% of the stock. Invesco Ltd invested in 69,879 shares or 0% of the stock. Barclays Pcl owns 187,549 shares for 0.02% of their portfolio. Envestnet Asset Management Inc holds 0% in Puma Biotechnology, Inc. (NASDAQ:PBYI) or 94 shares. Redwood Invs Lc owns 66,942 shares or 0.91% of their US portfolio. Ascend Ltd Liability Company owns 716,717 shares or 3.24% of their US portfolio. C Wide Group Inc A S owns 23,792 shares. Amer Century holds 51,984 shares. Citigroup Inc has invested 0% in Puma Biotechnology, Inc. (NASDAQ:PBYI). 2.55M are held by Vanguard Grp. Guggenheim Ltd has invested 0.01% in Puma Biotechnology, Inc. (NASDAQ:PBYI).

Perceptive Advisors Llc decreased Wave Life Sciences Ltd stake by 20,000 shares to 642,798 valued at $13.98M in 2017Q3. It also reduced Viveve Medical Inc stake by 403,480 shares and now owns 486,988 shares. Abeona Therapeutics Inc was reduced too.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: